<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Articles SYSTEM "HBI_DTD">
<Articles><Article><Journal><PublisherName></PublisherName><JournalTitle>International Journal of Preventive Medicine (Int J Prev Med)</JournalTitle><Issn>2008-7802</Issn><Volume>4</Volume><Issue>1</Issue><PubDate PubStatus="epublish"><Year>2013</Year><Month>05</Month><Day>05</Day></PubDate></Journal><title locale="en_US">Olanzapine Versus Haloperidol: Which Can Control Stuttering Better?</title><FirstPage>270</FirstPage><LastPage>273</LastPage><Language>EN</Language><AuthorList><Author><affiliation locale="en_US">Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation></Author><Author><affiliation locale="en_US">Department of Speech Therapy, Faculty of Rehabilitation, Tehran University of Medical Sciences, Tehran, Iran</affiliation></Author><Author><affiliation locale="en_US">Department of Speech Therapy, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation></Author><Author><affiliation locale="en_US">Department of Neurology, Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation></Author><Author><affiliation locale="en_US">Department of Neurology, Tehran University of Medical Sciences, Tehran, Iran</affiliation></Author><Author><affiliation locale="en_US">Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</affiliation></Author><Author><affiliation locale="en_US">Department of Medical Sciences, Najafabad Branch, Islamic Azad University, Isfahan, Iran</affiliation></Author></AuthorList><History><PubDate PubStatus="received"><Year>2013</Year><Month>05</Month><Day>05</Day></PubDate></History><abstract locale="en_US">&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The aim of this study was to compare the effects of olanzapine versus haloperidol to control the signs and symptoms of stuttering.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Ninety‑three patients were recruited in a 12‑week single‑blind randomized clinical trial, which was held between October 2009 and October 2010. Forty‑three patients received olanzapine (5 mg/day) and 50 patients, haloperidol (2.5 mg/day). Before and after the study, they were evaluated by a speech pathologist by Van Riper`s questionnaire. The data were analyzed using the SPSS version 16. T‑test was used to compare the data between the two groups.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Mean of stuttering score (SD) before treatment was 4.67 (0.81) and 4.40 (1.14) in haloperidol and olanzapine groups, respectively (&lt;em&gt;P &lt;/em&gt;&amp;gt; 0.05). After treatment, the mean (SD) score was 2.87 (1.32) and 1.56 (0.71) in haloperidol and olanzapine groups, respectively (&lt;em&gt;P &lt;/em&gt;= 0.000).&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;It seems that olanzapine does have better impact in controlling stuttering, and it may be recommended to prescribe olanzapine for stutters as the first choice to control the stuttering under a careful follow‑up.&lt;/p&gt; &lt;strong&gt;Keywords: &lt;/strong&gt;Haloperidol, olanzapine, stuttering</abstract><web_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/1172</web_url><pdf_url>http://ijpm.mui.ac.ir/index.php/ijpm/article/download/1172/959</pdf_url></Article></Articles>
